Company Overview and News

 
Paradigm Biopharmaceuticals achieves pain treatment win with AFL players

2018-04-05 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is witnessing remarkable results in AFL players treated with injectable pentosan polysulfate sodium (PPS) for crippling knee, hip and groin pain.
Upvote Downvote

 
Paradigm Biopharmaceuticals’ osteoarthritis trial remains ahead of schedule

2018-03-27 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd’s (ASX:PAR) phase 2b clinical trial in participants with knee osteoarthritis and concurrent bone marrow lesions is 50% recruited and remains ahead of schedule.
Upvote Downvote

 
Paradigm Biopharmaceuticals has success with PPS osteoarthritis treatment

2018-02-28 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has released promising information from trials of its injectable pentosan polysulfate sodium (PPS) treatment.
Upvote Downvote

 
Paradigm Biopharmaceuticals adds AFL legend to list of osteoarthritis treatment wins

2018-01-30 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has added AFL legend Greg ‘Diesel’ Williams to its growing list of elite sportspeople benefiting from pentosan polysulfate sodium (PPS) for osteoarthritis.
Upvote Downvote

 
Paradigm Biopharmaceuticals eyes opportunities to treat osteoarthritis

2018-01-24 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is witnessing a growing number of elite sportspeople being successfully treated by doctors with pentosan polysulfate sodium (PPS) for osteoarthritis.
Upvote Downvote

 
Paradigm Biopharmaceuticals granted European patent

2018-01-15 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has been granted a European patent for the treatment of bone marrow edema lesions with the drug pentosan polysulfate sodium (PPS).
Upvote Downvote

 
Paradigm Biopharmaceuticals meets primary endpoint in clinical trial

2017-11-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has received results from its phase 2a clinical trial in bone marrow lesions (bone bruising) as a result of an anterior cruciate ligament (ACL) injury.
Upvote Downvote

 
Paradigm Biopharmaceuticals funded into 2019 through placement

2017-11-06 proactiveinvestors.com.au
Paradigm Biopharmaceuticals (ASX:PAR) has completed a share placement to raise $5.75 million by issuing shares priced at $0.30 to institutional, sophisticated and professional investors.
Upvote Downvote

 
Paradigm Biopharmaceuticals to finalise raising

2017-11-01 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) remains focused on repurposing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation.
Upvote Downvote

 
Paradigm has successfully dosed first participant in clinical trial for osteoarthritis

2017-10-30 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has now dosed the first participant in the Phase 2b clinical trial at Emeritus Research in Malvern East, Victoria.
Upvote Downvote

 
Paradigm reveals outcomes from patient case studies on Osteoarthritis

2017-10-11 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has outlined the results of 24 patient case studies with Osteoarthritis (OA) and Bone Marrow Edema Lesions (BMELs) that were treated with Pentosan Polysulfate Sodium (PPS) under the Therapeutic Goods Administration’s (TGA) Special Access Scheme.
Upvote Downvote

 
Paradigm Biopharmaceuticals receives ethics approval for trial on knee osteoarthritis

2017-09-20 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has received ethics approval for its Phase 2b clinical trial to investigate Pentosan Polysulfate Sodium (PPS) in subjects with knee osteoarthritis (OA) and bone marrow edema lesions (BMELs).
Upvote Downvote

 
Paradigm Biopharmaceuticals shares continue uptrend on leverage to Pentosan Polysulfate Sodium

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has added another 2% to $0.40 in early trade, after jumping 40% yesterday, following a peer-reviewed publication.
Upvote Downvote

 
Paradigm Biopharmaceuticals shares jump 75% in morning trade

2017-09-16 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) has caught investor attention this morning with its shares jumping 75% following the publication of a peer-reviewed journal of the potential of Pentosan Polysulfate Sodium (PPS).
Upvote Downvote

 
Paradigm's Paul Rennie discusses momentum of the Ross River Virus Clinical Trial

2017-09-14 proactiveinvestors.com.au
Paradigm Biopharmaceuticals Ltd (ASX:PAR) continues to advance its Phase 2 Ross River Virus Clinical Trial, with 25% of the 24-participant total having now been dosed across the initial two trial sites in Geelong and Brisbane.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...